CONNECT WITH US
HealthTech

HealthTech

#ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer

Endpoints News logo

Published on

Add as a preferred source on Google
#ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer

Li Zhang of Sun Yat-sen University Cancer Center presents data from HERON-Lung01 at ESMO (Ayisha Sharma for Endpoints News)

EGFR-mu­tant lung can­cer is an ADC bat­tle­ground, with Chi­na lead­ing the charge

MADRID — Sev­er­al drug­mak­ers with an­ti­body-drug con­ju­gates are jock­ey­ing for a spot in EGFR-mu­tant non-small cell lung can­cer pa­tients who progress af­ter As­traZeneca’s Tagris­so. And it …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Corx­el to take oral GLP-1 pub­lic in the US via SPAC October 26, 2026

As­traZeneca's two-pill com­bo may ex­tend Tagris­so's life in lung can­cer October 25, 2026

Pfiz­er looks be­yond lung can­cer flop as BioN­Tech, Bris­tol My­ers show ear­ly ac­tiv­i­ty October 25, 2026

Mer­ck and Mod­er­na's can­cer vac­cine da­ta were 'a tri­umph of sci­ence.' And now, the work be­gins

BioN­Tech, Du­al­i­ty­Bio pon­der next steps for HER2 ADC af­ter 'mod­est' breast can­cer re­sults

Roche takes vic­to­ry lap with lung can­cer pil­l's win over Am­gen, Bris­tol My­ers

Swiss biotech Wind­ward Bio files for Nas­daq IPO to fund Chi­na-de­rived as­sets and in-house R&D

Bris­tol My­ers re­veals death in MS CAR-T tri­al, has an­swer for safe­ty sig­nal in lu­pus tri­al



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.